1 Department of Clinical Oncology, the Sir Y.K. Pao Centre for Cancer, The. Chinese University of Hong Kong, Shatin, Hong Kong, the People's Republic of China. ..... Fund for their continuing support of liver cancer research. References. 1.
Clinical Chemistry 49:5 752–760 (2003)
Proteomics and Protein Markers
Comprehensive Proteomic Profiling Identifies Serum Proteomic Signatures for Detection of Hepatocellular Carcinoma and Its Subtypes Terence C.W. Poon,1 Tai-Tung Yip,2 Anthony T.C. Chan,1 Christine Yip,2 Victor Yip,2 Tony S.K. Mok,1 Conrad C.Y. Lee,1 Thomas W.T. Leung,1 Stephen K.W. Ho,1 and Philip J. Johnson1,3*
Background: Detection of hepatocellular carcinoma (HCC) in patients with chronic liver disease (CLD) is difficult. We investigated the use of comprehensive proteomic profiling of sera to differentiate HCC from CLD. Methods: Proteomes in sera from 20 CLD patients with ␣-fetoprotein (AFP) 500 g/L, and postoperative sera from two HCC patients. Results: Among 2384 common serum proteomic features, 250 were significantly different between the HCC and CLD cases. Two-way hierarchical clustering differentiated HCC and CLD cases. Most HCC cases with advanced disease were clustered together and formed
two subgroups that contained significantly more cases with lymph node invasion or distant metastasis. For differentiation of HCC and CLD by an artificial network (ANN), the area under the ROC curve was 0.91 (95% confidence interval, 0.82–1.01; P
